SciBase Issues New Information Document for Share Rights Issue, Aims for SEK 58 Million
On September 14, 2026, SciBase Holding AB, a prominent global player in medical technology, particularly in dermatology, announced the publication of an information document pertaining to its latest rights issue. The company aims to raise around SEK 58 million through this initiative, as disclosed by its Board of Directors on September 3, 2026. This move is pivotal for SciBase as it seeks to enhance its operational capabilities and continue its mission in the field of skin health management.
This information document is readily accessible on SciBase's official website as well as on the website of Bergs Securities AB, which acts as the financial adviser and issuing agent for this rights issue. Notably, this document does not constitute a prospectus under European regulatory requirements and has not been validated by any regulatory authority. Hence, it mandates adherence to jurisdictional rules for its distribution, specifically excluding regions like the United States, Australia, and others where additional measures might be necessary.
The rights issue's structure allows shareholders the opportunity to subscribe to new shares. The subscription period is scheduled between September 15 and 29, 2026, making it crucial for current investors to act promptly if they wish to take part in this offering. Between September 15 and October 16, 2026, investors will also have the chance to trade these shares that are paid up during the subscription.
The announcement of this rights issue comes against the backdrop of continuing advancements in SciBase's products, particularly the Nevisense platform. Nevisense is a state-of-the-art point-of-care tool that leverages artificial intelligence to improve diagnostic accuracy in dermatological assessments. This innovative solution not only emphasizes the early detection and prevention of skin conditions but also aims to optimize healthcare interventions, thereby reducing costs associated with late-stage treatment.
SciBase has a rich history rooted in over two decades of research conducted at the prestigious Karolinska Institute in Stockholm, Sweden. This established background is a testament to the company's leadership and commitment to dermatology advancements. Since its inception, SciBase has been listed on the Nasdaq First North Growth Market exchange since June 2, 2015, further solidifying its market presence.
In preparation for the upcoming rights issue, SciBase has partnered with both Bergs Securities and Birchtree Advisory as financial consultants, while BAHR provides legal support. The timeline for the rights issue indicates an expected release of results on October 1, 2026, providing crucial feedback to both the company and its investors.
Investors interested in subscribed shares should visit both SciBase's and Bergs Securities’ websites for subscription forms and ongoing updates about the rights issue. Furthermore, stakeholders are encouraged to carefully review the information document as it provides essential insights into the risks and potential opportunities associated with this offering.
In conclusion, this rights issue mechanism not only opens doors for existing shareholders to increase their investment but also represents a focused effort by SciBase to secure financing for future innovations and expansions in dermatological technologies. The emphasis on early detection and preventive care remains at the forefront of SciBase’s objectives, underpinning its commitment to improving patient health and reducing unnecessary healthcare expenditures.
As the subscription date approaches, stakeholders and potential investors are advised to engage with the provided resources and exercise their rights in alignment with legal stipulations discussed in the information release. This undertaking is set to bolster SciBase's capacity to continue delivering cutting-edge solutions that embody its vision of proactive healthcare management, affirming its role as a leader in the medical technology sector.
This information document is readily accessible on SciBase's official website as well as on the website of Bergs Securities AB, which acts as the financial adviser and issuing agent for this rights issue. Notably, this document does not constitute a prospectus under European regulatory requirements and has not been validated by any regulatory authority. Hence, it mandates adherence to jurisdictional rules for its distribution, specifically excluding regions like the United States, Australia, and others where additional measures might be necessary.
The rights issue's structure allows shareholders the opportunity to subscribe to new shares. The subscription period is scheduled between September 15 and 29, 2026, making it crucial for current investors to act promptly if they wish to take part in this offering. Between September 15 and October 16, 2026, investors will also have the chance to trade these shares that are paid up during the subscription.
The announcement of this rights issue comes against the backdrop of continuing advancements in SciBase's products, particularly the Nevisense platform. Nevisense is a state-of-the-art point-of-care tool that leverages artificial intelligence to improve diagnostic accuracy in dermatological assessments. This innovative solution not only emphasizes the early detection and prevention of skin conditions but also aims to optimize healthcare interventions, thereby reducing costs associated with late-stage treatment.
SciBase has a rich history rooted in over two decades of research conducted at the prestigious Karolinska Institute in Stockholm, Sweden. This established background is a testament to the company's leadership and commitment to dermatology advancements. Since its inception, SciBase has been listed on the Nasdaq First North Growth Market exchange since June 2, 2015, further solidifying its market presence.
In preparation for the upcoming rights issue, SciBase has partnered with both Bergs Securities and Birchtree Advisory as financial consultants, while BAHR provides legal support. The timeline for the rights issue indicates an expected release of results on October 1, 2026, providing crucial feedback to both the company and its investors.
Investors interested in subscribed shares should visit both SciBase's and Bergs Securities’ websites for subscription forms and ongoing updates about the rights issue. Furthermore, stakeholders are encouraged to carefully review the information document as it provides essential insights into the risks and potential opportunities associated with this offering.
In conclusion, this rights issue mechanism not only opens doors for existing shareholders to increase their investment but also represents a focused effort by SciBase to secure financing for future innovations and expansions in dermatological technologies. The emphasis on early detection and preventive care remains at the forefront of SciBase’s objectives, underpinning its commitment to improving patient health and reducing unnecessary healthcare expenditures.
As the subscription date approaches, stakeholders and potential investors are advised to engage with the provided resources and exercise their rights in alignment with legal stipulations discussed in the information release. This undertaking is set to bolster SciBase's capacity to continue delivering cutting-edge solutions that embody its vision of proactive healthcare management, affirming its role as a leader in the medical technology sector.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.